Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07529951Phase 1Not Yet Recruiting

Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers

Role: lead

NCT07524140Phase 1Not Yet Recruiting

Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts.

Role: lead

NCT07234864Phase 1Recruiting

Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients.

Role: lead

NCT06780124Phase 1Completed

Сlinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers

Role: lead

All 4 trials loaded